Exicure to Present at Upcoming Scientific Conferences

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR), a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences this October. The 17th International Congress on Neuronal Ceroid Lipofuscinosis will feature a presentation on Spherical Nucleic Acids targeting CLN3 for Batten Disease by Grant Corbett on October 8, 2021. Additionally, the International Oligonucleotides and Peptides Conference will see Matthias Schroff discussing their technology on October 18, 2021. Exicure focuses on innovative treatments for various neurological and genetic disorders.

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc.^® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced presentations in the following scientific conferences during the month of October:

17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs)
Title: "Development of Spherical Nucleic Acids Targeting CLN3 for the Treatment of Batten Disease"
Presented by: Grant Corbett, Group Lead, Neuroscience
Date: Friday, October 8, 2021
Time: 4:50 - 5:05 PM CDT

International OligonucIeotides and Peptides Conference (IOPC) 2021
Title: “Spherical Nucleic Acids Facilitate Efficient Local Delivery Across Therapeutic Areas”
Presented by: Matthias Schroff, COO
Date: Monday, October 18, 2021
Time: 8:55 - 9:25 AM CDT

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005139/en/

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com

Source: Exicure, Inc.

FAQ

What is Exicure's stock symbol?

Exicure's stock symbol is XCUR.

When is Exicure's presentation at the International Congress on Neuronal Ceroid Lipofuscinosis?

Exicure's presentation at the International Congress on Neuronal Ceroid Lipofuscinosis is on October 8, 2021.

Who is presenting at the IOPC for Exicure?

Matthias Schroff, COO of Exicure, will present at the IOPC on October 18, 2021.

What topics will Exicure present at the conferences in October 2021?

Exicure will present topics on Spherical Nucleic Acids targeting CLN3 for Batten Disease and efficient local delivery across therapeutic areas.

What therapeutic areas does Exicure focus on?

Exicure focuses on neurology, immuno-oncology, inflammatory diseases, and genetic disorders.